Complete remission following lenalidomide and rituximab in a patient with heavily pretreated nodular lymphocyte predominant Hodgkin lymphoma

Leuk Lymphoma. 2016 Aug;57(8):1974-6. doi: 10.3109/10428194.2015.1124993. Epub 2016 Jan 13.

Authors

Chan Yoon Cheah¹, Haleigh E Mistry¹, Sergej Konoplev², Nathan H Fowler¹

Affiliations

¹ a Department of Lymphoma and Myeloma , The University of Texas MD Anderson Cancer Center , Houston , TX , USA ;
² b Department of Pathology , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

PMID: 26762971
DOI: 10.3109/10428194.2015.1124993

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Female
Hodgkin Disease / drug therapy*
Hodgkin Disease / pathology
Humans
Lenalidomide
Lymphocytes / drug effects*
Lymphocytes / pathology
Remission Induction
Rituximab / administration & dosage
Thalidomide / administration & dosage
Thalidomide / analogs & derivatives
Treatment Outcome

Substances

Rituximab
Thalidomide
Lenalidomide